JEWJITSU PEPTIDES: Recent primary reports on GLP‑1 cardiovascular roles, tripeptide siRNA nanogels, and FGFR2b in iCCA

This review article synthesizes existing clinical outcome trials and mechanistic literature on glucagon‑like peptide‑1 (GLP‑1) receptor agonists and dual GIP‑GLP‑1 agonists. The authors report that these incretin‑based therapies were developed for type 2 diabetes but have been studied for cardiovascular effects, with large cardiovascular outcome trials showing reductions in major adverse cardiovascular events among patients with type 2 diabetes and elevated cardiovascular risk. The review also notes expanded interest in obesity treatment, possible roles in selected heart failure with preserved ejection fraction populations, and proposes integrated metabolic, inflammatory, vascular, and hemodynamic mechanisms. The paper discusses safety considerations and outlines future clinical application directions across the cardiometabolic continuum, while being a synthesis rather than a primary randomized trial itself.

The biomaterials study evaluates three N‑capped tripeptides (2NapKFF, 2NapFKF, 2NapFFK) formulated into hydrogels and derived nanogels to load siRNA by electrostatic interactions. Reported findings include about 99% encapsulation efficiency for all tripeptides and a clear dependence of network stability and mechanical properties on the lysine position within the sequence. The authors identify 2NapFKF as the most suitable candidate, noting a particle size near 200 nm compatible with parenteral administration and surfactant stabilization. In vitro assays in HEK293 cells indicated biocompatibility, cytoplasmic internalization via endocytic pathways, and preservation of mitotic activity. The study presents promising delivery attributes but is limited to in vitro characterization and a specific cell line model.

The proteogenomic report applies an isoform‑resolved workflow (integrating transcriptomics, in silico translation, and cell surfaceomics) to identify tumor‑enriched cell surface targets in intrahepatic cholangiocarcinoma (iCCA). The authors found an FGFR2 splice isoform, FGFR2b, to be the predominant FGFR2 form in biliary tract cancers in their institutional cohort (reported 88.6%) and in TCGA (reported 88.2%). FGFR2 fusions were associated with high FGFR2b expression; high FGFR2b correlated in their analyses with improved surgical outcomes, epithelial differentiation, and reduced CD8+ T‑cell infiltration. Orthogonal immunohistochemistry in a 20‑patient subset detected membrane FGFR2b in about 31.6% of cases, including all with FGFR2 fusions. The report highlights FGFR2b as a candidate cell‑surface target while noting the need for further validation and development for therapeutic targeting.